This page shows the latest trial data news and features for those working in and with pharma, biotech and healthcare.
Amgen and Novartis’much-anticipated new migraine drug Aimovig has generated positive data in another late-stage trial, halving migraine days in 30% of patients with continued symptoms despite multiple earlier ... The new data comes just a month before
Merck’ s Keytruda meets survival challenge in NSCLC. Data showed that almost 70% of patients on the combo were still alive after 12 months. ... failing to show a benefit in an all-comer pivotal trial in 2016.
Approval wasn’t assured however, particularly as the initial read-out from the CheckMate-214 trial underpinning the filing was mixed. ... Positive data from a first-line NSCLC trial were reported at the American Association of Cancer Research (AACR)
AZ makes case for first-line Tagrisso therapy in lung cancer. Data shows the drug improved PFS versus older EGFR inhibitors including Roche’s Tarceva. ... AstraZeneca says that new data from its FLAURA trial of EGFR inhibitor Tagrisso makes a
Interim data suggested there was no improvement on disease-free survival compared to placebo. ... been called to a halt after an interim look at the data suggested there was no clear benefit.
AbbVie’ s upadacitinib aces phase III trial. Arthritis drug outperformed both placebo and Humira in the study. ... AbbVie’s JAK1 inhibitor upadacitinib has proved more effective than the company’s widely-used TNF blocker Humira in a phase III trial
More from news
Approximately 45 fully matching, plus 633 partially matching documents found.
The rise of real-world evidence. Demonstrating efficacy and value requires more than clinical trial data. ... Whatever technology patients are using, we have a way to pull in that data.
The company switched focus to its JCAR017 programme and recently reported promising data in a pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). ... Tucatinib is currently being evaluated in a phase II pivotal trial in
According to this draft, overseas clinical trial data provided by the MAHs for the drug registration in China shall be complete, correct, true and traceable. ... The process of obtaining the overseas clinical trial data shall comply with both Good
GalNAc technology does hold potential, but has limited utility, and a recent trial suspension using this technology has not yet been fully resolved. ... Therefore, the use of sub-optimal delivery vectors may continue to result in disappointing trial data
Trial Management Systems (CTMS) and Clinical Data Management Systems (CDMS). ... Quintiles, the world’s largest contract research organisation, has differentiated itself by providing its customers with a real-time view of clinical trial data so they
More from intelligence
Approximately 0 fully matching, plus 35 partially matching documents found.
Clinerion appoints new regional head. Bariş Erdoğan takes up new role at the clinical trial data firm. ... Swiss-based clinical trial data firm Clinerion has appointed Bariş Erdoğan as its new regional head in a role that focuses on the expansion of
One of the most pressing matters for EFPIA is the seemingly inevitable trend towards transparency of trial data, and Viehbacher has already commented on the subject.
Eric Green named NIH's data science lead. Takes role on interim basis as part of expanding plans for data. ... This project offers a data repository with demographics, clinical observations, clinical trial outcomes, adverse events and biomarker data like
According to the company, which provides services to the pharma industry, he will oversee the development of its IXRS technology to manage patients, supplies, and clinical trial data.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Further, the tolerability was in favor of pembrolizumab. We talked Dr Martin Reck about the trial. ... He explains that “ this data will completely change our management of patients with advanced lung cancer”.
The challenge is to turn that data into information and information into insight. ... In tandem, as the limitations of the 'gold standard' randomised clinical trial (RCT) data are increasingly exposed, European initiatives such as the Innovative
Flagship policy in both Europe and the US is mandating the full disclosure of clinical trial data, while international regulations now dictate data sharing, including anonymised individual-patient data, across all ... Although these approaches are still
This often means that manufacturers will only have trial data for part of the label population (based on a single phase 3 trial). ... There is also a risk that if the trial population is segmented and data has not been collected for the relevant segments
As the date for legislation approaches, each week brings more debate regarding the issue of clinical data transparency. ... But despite simplistic reporting, the issue of increasing the transparency of data from clinical trials contains complexities not
More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...